Assessment of hepatitis B vaccine-induced seroprotection among children 5-10 years old in Ulaanbaatar, Mongolia.
暂无分享,去创建一个
Moazzam Ali | C. Kuroiwa | Moazzam Ali | Chushi Kuroiwa | Tumendemberel Ochirbat | Nymadawa Pagbajab | Lkhagva-Ochir Erkhembaatar | Enkhtuya Budbazar | Naryad Sainkhuu | Erkhembaatar Tudevdorj | Nymadawa Pagbajab | L. Erkhembaatar | Tumendemberel Ochirbat | Enkhtuya Budbazar | Naryad Sainkhuu | E. Tudevdorj
[1] T. Nishizawa,et al. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia , 2006, Journal of medical virology.
[2] S. Wiersma,et al. Progress in the control of hepatitis B infection in the Western Pacific Region. , 2006, Vaccine.
[3] Y. Hutin,et al. Rapid assessment of injection practices in Mongolia. , 2004, American journal of infection control.
[4] P. Nymadawa,et al. Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. , 2002, Preventive medicine.
[5] European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? , 2000, The Lancet.
[6] T. Nishizawa,et al. High Prevalence of Antibodies to Hepatitis A and E Viruses and Viremia of Hepatitis B, C, and D Viruses among Apparently Healthy Populations in Mongolia , 2004, Clinical Diagnostic Laboratory Immunology.
[7] M. On,et al. Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. , 1999, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[8] Hong-jian Yan,et al. Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. , 2006, Vaccine.
[9] Sheng-Nan Lu,et al. Hepatitis B virus infection in adolescents in a rural township--15 years subsequent to mass hepatitis B vaccination in Taiwan. , 2006, Vaccine.
[10] T. Altantsetseg,et al. Emerging Infectious Diseases in Mongolia , 2003, Emerging infectious diseases.
[11] M. Chang,et al. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. , 1995, The Journal of pediatrics.
[12] B. McMahon,et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. , 2005, Vaccine.
[13] A. Zanetti,et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study , 2005, The Lancet.
[14] M. Miyoshi,et al. Non-polio enterovirus isolation among families in Ulaanbaatar and Tov province, Mongolia: prevalence, intrafamilial spread, and risk factors for infection , 2005, Epidemiology and Infection.
[15] James S Edstam,et al. Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia. , 2004, Preventive medicine.
[16] O. N. Mohamed,et al. Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. , 1999, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[17] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .
[18] M. Yuen,et al. Twelve‐year follow‐up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma‐derived vaccine without booster doses in children , 1999, Hepatology.
[19] M. Yuen,et al. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] P. Chou,et al. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. , 2002, The American journal of tropical medicine and hygiene.
[21] M. Kane. Global status of hepatitis B immunisation , 1996, The Lancet.
[22] J M Lepkowski,et al. Socioeconomic factors, health behaviors, and mortality: results from a nationally representative prospective study of US adults. , 1998, JAMA.
[23] S. Twu,et al. Waning immunity to plasma‐derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination , 2004, Hepatology.
[24] H. Margolis,et al. Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up , 2005, Annals of Internal Medicine.
[25] B. McMahon,et al. Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth , 2004, The Pediatric infectious disease journal.
[26] A MarioCalvo,et al. Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up , 2005 .